Epitiostanol
Overview[edit]
Epitiostanol is a synthetic anabolic-androgenic steroid (AAS) that was developed in the 1960s. It is primarily known for its use in the treatment of breast cancer. Epitiostanol is a derivative of dihydrotestosterone (DHT) and is characterized by its unique chemical structure, which includes a sulfur atom.
Chemical Structure[edit]
Epitiostanol is chemically known as 2_,3_-epithio-5_-androstan-17_-ol. The presence of the epithio group (a sulfur atom replacing an oxygen atom) in its structure is a distinguishing feature that contributes to its biological activity.
Mechanism of Action[edit]
Epitiostanol functions as an anti-estrogenic agent. It binds to estrogen receptors in breast tissue, thereby inhibiting the growth of estrogen-dependent tumors. Unlike other anti-estrogens, epitiostanol does not exhibit estrogenic activity, making it a pure anti-estrogen.
Medical Uses[edit]
Epitiostanol was primarily used in the treatment of breast cancer, particularly in postmenopausal women. Its ability to inhibit estrogen-dependent tumor growth made it a valuable therapeutic option before the advent of more modern treatments.
Pharmacokinetics[edit]
Epitiostanol is administered via injection due to its poor oral bioavailability. Once administered, it is metabolized in the liver and excreted primarily through the urine.
Side Effects[edit]
As with other anabolic-androgenic steroids, epitiostanol can cause a range of side effects. These may include:
- Virilization in women
- Liver toxicity
- Changes in lipid profile
Discontinuation[edit]
The use of epitiostanol has largely been discontinued in favor of newer, more effective treatments for breast cancer, such as tamoxifen and aromatase inhibitors.
Related Compounds[edit]
Epitiostanol is related to other anabolic-androgenic steroids, such as oxandrolone and stanozolol, which also have medical applications but differ in their specific uses and side effect profiles.
